The utility of epithelial membrane antigen and vimentin in the diagnosis of chromophobe renal cell carcinoma.
The utility of epithelial membrane antigen and vimentin in the diagnosis of chromophobe renal cell carcinoma.
复制标题
DOI：
10.1053/adpa.2002.33901
复制
发表时间：
2002-06-01
影响因子：
2
通讯作者：
MacLennan, Gregory T
中科院分区：
文献类型：
--
作者：
Khoury, Joseph D;Abrahams, Neil A;MacLennan, Gregory T
目的：探讨肾嫌色细胞癌（CHRCC）中上皮膜抗原（EMA）和波形蛋白（VMT）的免疫组化表达。我们还研究了EMA和VMT免疫染色在帮助区分CHRCC与肾嗜酸细胞瘤和常规（透明细胞）颗粒状肾细胞癌（GCRCC）中的作用。对21例CHRCC、16例肾嗜酸细胞瘤和28例GCRCC进行EMA和VMT免疫组化染色。所有病例的诊断均由参与研究的所有病理学家一致同意，并完全基于常规染色载玻片的检查。所有病例都是这些肿瘤类型的典型例子，没有诊断困难。免疫组织化学染色的强度按0 - 3分进行分级（0 =无染色; 1 =不确定; 2 =明确，中等强度; 3 =明确，高强度）。阳性免疫组化染色定义为至少20%的肿瘤细胞明确染色。所有CHRCC均为EMA阳性，VMT阴性。75%的肾嗜酸细胞瘤和21%的GCRCC具有相同的免疫表型。总之，在我们的研究中，所有CHRCC病例均显示EMA免疫组化染色，而非VMT。然而，我们也发现，在75%的肾嗜酸细胞瘤和21%的GCRCC中观察到相同的免疫表型，排除了其用于CHRCC阳性鉴别的实用性。然而，缺乏这种免疫表型是一个可靠的迹象，肿瘤正在考虑不是CHRCC。
We evaluated the immunohistochemical expression of epithelial membrane antigen (EMA) and vimentin (VMT) in chromophobe renal cell carcinoma (CHRCC). We also studied the utility of EMA and VMT immunostains in helping differentiate CHRCC from renal oncocytoma and conventional (clear cell) renal cell carcinoma with granular morphology (GCRCC). Immunohistochemical staining for EMA and VMT was performed on 21 cases of CHRCC, 16 cases of renal oncocytoma, and 28 cases of GCRCC. The diagnosis in all cases was by concurrence of all pathologists involved in the study and was based entirely on examination of routinely stained slides. All cases were classic examples of these tumor types and presented no diagnostic difficulties. The intensity of immunohistochemical staining was graded on a scale of 0 to 3 (0 = no staining; 1 = equivocal; 2 = unequivocal, moderate intensity; and 3 = unequivocal, high intensity). Positive immunohistochemical staining was defined as unequivocal staining of at least 20% of the neoplastic cells. All cases of CHRCC were positive for EMA and negative for VMT. The same immunophenotype was observed in 75% of renal oncocytoma and 21% of GCRCC. In summary, all CHRCC cases in our study demonstrated immunohistochemical staining for EMA and not VMT. However, we also found that the same immunophenotype is observed in 75% of renal oncocytoma and in 21% of GCRCC, precluding its utility for positive identification of CHRCC. Nevertheless, the lack of such an immunophenotype is a reliable indication that a neoplasm under consideration is not CHRCC.